390 related articles for article (PubMed ID: 26005708)
1. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.
Kwilas AR; Donahue RN; Tsang KY; Hodge JW
Cancer Cell Microenviron; 2015; 2(1):. PubMed ID: 26005708
[TBL] [Abstract][Full Text] [Related]
2. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
Farsaci B; Donahue RN; Coplin MA; Grenga I; Lepone LM; Molinolo AA; Hodge JW
Cancer Immunol Res; 2014 Nov; 2(11):1090-102. PubMed ID: 25092771
[TBL] [Abstract][Full Text] [Related]
3. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.
Kwilas AR; Ardiani A; Donahue RN; Aftab DT; Hodge JW
J Transl Med; 2014 Nov; 12():294. PubMed ID: 25388653
[TBL] [Abstract][Full Text] [Related]
4. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
Qiang H; Chang Q; Xu J; Qian J; Zhang Y; Lei Y; Han B; Chu T
J Cancer Res Clin Oncol; 2020 Mar; 146(3):631-645. PubMed ID: 32065262
[TBL] [Abstract][Full Text] [Related]
5. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ; Chen JX; Sun ZJ
Cancer Commun (Lond); 2021 Sep; 41(9):830-850. PubMed ID: 34137513
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
8. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.
Walraven M; Homs MYV; van der Veldt AAM; Dekker H; Koldenhof J; Honeywell R; Barendrecht A; Sebastian SAE; Parr N; Koekman AC; Voest EE; Roest M; Korporaal SJA; Verheul HMW
Angiogenesis; 2018 May; 21(2):325-334. PubMed ID: 29532289
[TBL] [Abstract][Full Text] [Related]
9. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.
Zhu N; Weng S; Wang J; Chen J; Yu L; Fang X; Yuan Y
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3021-3036. PubMed ID: 31617075
[TBL] [Abstract][Full Text] [Related]
10. The role of antiangiogenetic agents in the treatment of breast cancer.
Bareschino MA; Schettino C; Colantuoni G; Rossi E; Rossi A; Maione P; Ciardiello F; Gridelli C
Curr Med Chem; 2011; 18(33):5022-32. PubMed ID: 22050750
[TBL] [Abstract][Full Text] [Related]
11. Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity.
Reguera-Nuñez E; Man S; Xu P; Hilberg F; Kerbel RS
Angiogenesis; 2019 Nov; 22(4):535-546. PubMed ID: 31463627
[TBL] [Abstract][Full Text] [Related]
12. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy.
Aparicio LMA; Fernandez IP; Cassinello J
Clin Transl Oncol; 2017 Oct; 19(10):1175-1182. PubMed ID: 28409322
[TBL] [Abstract][Full Text] [Related]
14. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Lee FY; Covello KL; Castaneda S; Hawken DR; Kan D; Lewin A; Wen ML; Ryseck RP; Fairchild CR; Fargnoli J; Kramer R
Clin Cancer Res; 2008 Dec; 14(24):8123-31. PubMed ID: 19088027
[TBL] [Abstract][Full Text] [Related]
16. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
Petrazzuolo A; Maiuri MC; Zitvogel L; Kroemer G; Kepp O
Oncoimmunology; 2022; 11(1):2077898. PubMed ID: 35655707
[TBL] [Abstract][Full Text] [Related]
17. Strategies targeting angiogenesis in advanced non-small cell lung cancer.
Wang J; Chen J; Guo Y; Wang B; Chu H
Oncotarget; 2017 Aug; 8(32):53854-53872. PubMed ID: 28881856
[TBL] [Abstract][Full Text] [Related]
18. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.
Gao L; Yang X; Yi C; Zhu H
Front Pharmacol; 2019; 10():1173. PubMed ID: 31680957
[No Abstract] [Full Text] [Related]
19. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Nagano T; Tachihara M; Nishimura Y
Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
